WuXi XDC Cayman Inc. (HKG:2268)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
67.50
+2.10 (3.21%)
Sep 8, 2025, 4:08 PM HKT
3.21%
Market Cap81.34B
Revenue (ttm)5.58B
Net Income (ttm)1.45B
Shares Out1.21B
EPS (ttm)1.12
PE Ratio60.36
Forward PE40.98
Dividendn/a
Ex-Dividend Daten/a
Volume4,691,698
Average Volume9,020,537
Open65.95
Previous Close65.40
Day's Range64.95 - 67.50
52-Week Range18.52 - 69.00
Betan/a
RSI65.38
Earnings DateAug 18, 2025

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China.... [Read more]

Sector Healthcare
Founded 2013
Employees 2,041
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2268
Full Company Profile

Financial Performance

In 2024, WuXi XDC Cayman's revenue was 4.05 billion, an increase of 90.80% compared to the previous year's 2.12 billion. Earnings were 1.07 billion, an increase of 277.24%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.